These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 20510041)

  • 1. [Expression of CD123 in lymphocytic leukemia and its significance for monitoring minimal residual diseases.].
    Wang YF; Chen BG; Luo WD; Zheng R; Li BL
    Zhonghua Xue Ye Xue Za Zhi; 2010 Apr; 31(4):244-8. PubMed ID: 20510041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-3 receptor α chain (CD123) is preferentially expressed in immature T-ALL and may not associate with outcomes of chemotherapy.
    Du W; Li J; Liu W; He Y; Yao J; Liu Y; Lin J; Zheng J
    Tumour Biol; 2016 Mar; 37(3):3817-21. PubMed ID: 26474588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of CD34/CD123 expression in detection of minimal residual disease in B-ACUTE lymphoblastic leukemia in children.
    Zeidan MA; Kamal HM; El Shabrawy DA; Esh AM; Sattar RH
    Blood Cells Mol Dis; 2016 Jul; 59():113-8. PubMed ID: 27282579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia.
    Veltroni M; De Zen L; Sanzari MC; Maglia O; Dworzak MN; Ratei R; Biondi A; Basso G; Gaipa G;
    Haematologica; 2003 Nov; 88(11):1245-52. PubMed ID: 14607753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunophenotypic Characterization of Cytogenetic Subgroups in Egyptian Pediatric Patients With B-Cell Acute Lymphoblastic Leukemia.
    Adnan Awad S; Kamel MM; Ayoub MA; Kamel AM; Elnoshokaty EH; El Hifnawi N
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S19-S24.e1. PubMed ID: 27521317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical significance for minimal residual disease detection by 4 color flow cytometry in adult and childhood B lineage acute lymphoblastic leukemia].
    Liu YR; Zhang LP; Chang Y; Cheng YF; Fu JY; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):302-5. PubMed ID: 16875577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
    van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ
    Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Application of CD123 in detection of minimal residual disease in acute promyelocytic leukemia].
    Wang YZ; Chang Y; Zhu HH; Qin YZ; Li JL; Fu JY; Li LD; Chen SS; Huang XJ; Lu DP; Liu YR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun; 14(3):427-32. PubMed ID: 16800913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry.
    Dowling AK; Liptrot SD; O'Brien D; Vandenberghe E
    Lab Med; 2016 May; 47(2):103-11. PubMed ID: 27069028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The application of CD73 in minimal residual disease monitoring using flow cytometry in B-cell acute lymphoblastic leukemia.
    Wang W; Gao L; Li Y; Li ZL; Gong M; Huang FZ; Chen YR; Zhang CX; Gao YY; Ma YG
    Leuk Lymphoma; 2016 May; 57(5):1174-81. PubMed ID: 26436205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Real-world Perspective of CD123 Expression in Acute Leukemia as Promising Biomarker to Predict Treatment Outcome in B-ALL and AML.
    Das N; Gupta R; Gupta SK; Bakhshi S; Malhotra A; Rai S; Singh S; Prajapati VK; Sahoo RK; Gogia A; Sharma A; Kumar L
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e673-e684. PubMed ID: 32561191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping.
    Bras AE; de Haas V; van Stigt A; Jongen-Lavrencic M; Beverloo HB; Te Marvelde JG; Zwaan CM; van Dongen JJM; Leusen JHW; van der Velden VHJ
    Cytometry B Clin Cytom; 2019 Mar; 96(2):134-142. PubMed ID: 30450744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.
    Angelova E; Audette C; Kovtun Y; Daver N; Wang SA; Pierce S; Konoplev SN; Khogeer H; Jorgensen JL; Konopleva M; Zweidler-McKay PA; Medeiros LJ; Kantarjian HM; Jabbour EJ; Khoury JD
    Haematologica; 2019 Apr; 104(4):749-755. PubMed ID: 30361418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies.
    Muñoz L; Nomdedéu JF; López O; Carnicer MJ; Bellido M; Aventín A; Brunet S; Sierra J
    Haematologica; 2001 Dec; 86(12):1261-9. PubMed ID: 11726317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The significance of peripheral blood minimal residual disease to predict early disease response in patients with B-cell acute lymphoblastic leukemia.
    Setiadi A; Owen D; Tsang A; Milner R; Vercauteren S
    Int J Lab Hematol; 2016 Oct; 38(5):527-34. PubMed ID: 27339737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
    Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
    Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical significance of dynamic monitoring the minimal residual disease in childhood B-lineage acute lymphoblastic leukemia by multiparameter flow cytometry].
    Guo DD; Zhao WL; Zhang YL; Pang L; Che L; He HL; Chai YH; Ji ZH; Ji XQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1346-51. PubMed ID: 23257430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry.
    Solly F; Angelot F; Garand R; Ferrand C; Seillès E; Schillinger F; Decobecq A; Billot M; Larosa F; Plouvier E; Deconinck E; Legrand F; Saas P; Rohrlich PS; Garnache-Ottou F
    Cytometry A; 2012 Jan; 81(1):17-24. PubMed ID: 22052678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.
    Moreton P; Kennedy B; Lucas G; Leach M; Rassam SM; Haynes A; Tighe J; Oscier D; Fegan C; Rawstron A; Hillmen P
    J Clin Oncol; 2005 May; 23(13):2971-9. PubMed ID: 15738539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
    Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
    Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.